

**Summit Corporation plc**  
 (“Summit plc” or “the Company”)

**DIRECTOR AND PDMR SHARE DEALINGS**

**Oxford, UK, 4 August 2010**, Summit (AIM: SUMM), a UK drug discovery Company with an innovative Seglin™ technology platform and a portfolio of partner funded programmes, has been notified about the following purchase of One pence Ordinary Shares in Summit by the Executive Management team of the Company:

<b>Name of Director</b>	<b>Position</b>	<b>Shares Purchased</b>	<b>Date of Purchase</b>	<b>Price per Share</b>	<b>Current Holding</b>	<b>% of Issued Share Capital</b>
Steven Lee, PhD	CEO	150,000	03/08/2010	3.0p	2,582,492	1.55%
Richard Storer, DPhil	CSO	100,000	03/08/2010	3.0p	676,229	0.41%
<b>Name of Senior Manager</b>	<b>Position</b>	<b>Shares Purchased</b>	<b>Date of Purchase</b>	<b>Price per Share</b>	<b>Current Holding</b>	<b>% of Issued Share Capital</b>
Raymond Spencer, ACA	CFO	400,000	03/08/2010	2.93p	1,200,000	0.72%

Following these share purchases, the total holdings of the Directors and PDMR of the Company is 8.2% of the issued share capital of the Company.

- END -

**For more information, please contact:**

**Summit**

Steven Lee, PhD  
 Richard Pye, PhD

Tel: +44 (0)1235 443 951

**Singer Capital Markets (Nominated Adviser)**

Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500

**Peckwater PR**

Tarquin Edwards

Tel: +44 (0)7879 458 364

[tarquin.edwards@peckwaterpr.co.uk](mailto:tarquin.edwards@peckwaterpr.co.uk)

## **About Summit plc**

Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins<sup>™</sup> for the discovery of new medicines, a portfolio of partner funded drug programmes and a commercial strategy of signing multiple early-stage deals

Seglin<sup>™</sup> technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches. Summit's internal research is currently focussed in the high value therapy areas of type II diabetes and infectious diseases and the Company will further exploit the technology's wider potential through strategic alliances. Summit's portfolio of partner funded drug programmes require no further investment from the Company but have the potential to deliver future upside for the business.

Summit's commercial strategy focuses on signing multiple early-stage drug programme and technology platform deals that generate upfront cash, remove development costs and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at [www.summitplc.com](http://www.summitplc.com).